Your browser is no longer supported. Please, upgrade your browser.
ARNA Arena Pharmaceuticals, Inc. monthly Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.38 Insider Own0.59% Shs Outstand243.25M Perf Week-3.45%
Market Cap340.56M Forward P/E- EPS next Y-0.33 Insider Trans-1.29% Shs Float242.12M Perf Month-4.76%
Income-91.50M PEG- EPS next Q-0.08 Inst Own50.50% Short Float5.26% Perf Quarter-11.95%
Sales46.40M P/S7.34 EPS this Y-62.90% Inst Trans1.29% Short Ratio7.39 Perf Half Y-32.04%
Book/sh0.01 P/B140.00 EPS next Y2.90% ROA-39.50% Target Price3.75 Perf Year-26.70%
Cash/sh0.42 P/C3.35 EPS next 5Y- ROE-339.10% 52W Range1.30 - 2.16 Perf YTD-26.32%
Dividend- P/FCF- EPS past 5Y17.00% ROI-84.70% 52W High-35.19% Beta-0.70
Dividend %- Quick Ratio2.10 Sales past 5Y18.20% Gross Margin73.50% 52W Low7.69% ATR0.08
Employees228 Current Ratio2.20 Sales Q/Q111.00% Oper. Margin- RSI (14)36.72 Volatility5.73% 5.50%
OptionableYes Debt/Eq20.03 EPS Q/Q53.40% Profit Margin- Rel Volume1.04 Prev Close1.48
ShortableYes LT Debt/Eq19.00 EarningsNov 07 AMC Payout- Avg Volume1.72M Price1.40
Recom2.70 SMA20-9.31% SMA50-12.58% SMA200-16.61% Volume1,771,333 Change-5.41%
Sep-15-16Initiated FBR & Co. Outperform $6
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $2 → $1.50
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Oct-28-15Reiterated WallachBeth Buy $6 → $4
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Sep-21-09Downgrade Leerink Swann Outperform → Mkt Perform $6
Sep-18-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
Dec-07-16 08:30AM  Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH) PR Newswire -5.41%
Dec-02-16 02:47PM  The Worst Marijuana Stocks in 2016 at Motley Fool
Nov-30-16 08:30AM  Arena Pharmaceuticals Announces Four Upcoming Presentations at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference PR Newswire
Nov-28-16 06:52PM  Should You Follow Hedge Funds Into Healthways, Inc. (HWAY)? at Insider Monkey -5.30%
11:52AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : November 28, 2016
Nov-22-16 11:08AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-17-16 01:04PM  ARENA PHARMACEUTICALS INC Financials
Nov-15-16 01:12PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : November 15, 2016
Nov-14-16 07:56AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : November 14, 2016
Nov-09-16 04:30PM  Arena Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference PR Newswire
04:09PM  ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
08:30AM  Arena Pharmaceuticals Announces Poster at the American Heart Association (AHA) Scientific Sessions 2016 PR Newswire
Nov-08-16 11:06AM  3 Things You Really Need to Know About Arena Pharmaceuticals, Inc. Q3 Results at Motley Fool
08:11AM  Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise
07:29AM  Arena Pharmaceuticals Shed Even More Weight in October at Motley Fool
Nov-07-16 06:37PM  Edited Transcript of ARNA earnings conference call or presentation 7-Nov-16 9:30pm GMT +5.76%
05:40PM  Arena Pharmaceuticals reports 3Q loss
04:37PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Arena Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q3 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Nov-04-16 05:39PM  Arena (ARNA) Q3 Earnings: Will the Stock Pull a Surprise?
Nov-03-16 08:05AM  Eisai and Arena Pharmaceuticals Announce Presentation of BELVIQ® (lorcaserin HCl) Data at 2016 Annual Obesity Week Meeting PR Newswire
Oct-31-16 04:30PM  Arena Pharmaceuticals to Release Third Quarter 2016 Financial Results and Provide Corporate Update on Monday, November 7, 2016 PR Newswire
Oct-28-16 01:33PM  Telling a Half-Truth Doesn't Work for Drugmaker at Bloomberg
Oct-18-16 09:23AM  Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status CNW Group
Oct-17-16 09:50AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : October 17, 2016
08:44AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : October 17, 2016
Oct-11-16 11:14AM  Why Arena Pharmaceuticals Is Finally Showing Some Signs of Life at Motley Fool
08:30AM  Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting PR Newswire
Oct-04-16 05:41PM  New Tablet Supports Weight Loss Management (ARNA) at Investopedia
Oct-03-16 09:14PM  BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States ACN Newswire
10:21AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : October 3, 2016
09:01AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
08:06AM  Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets PR Newswire
Sep-19-16 03:48PM  Arena Launches Drug Discovery Incubator (ARNA) at Investopedia
11:09AM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : September 19, 2016
Sep-16-16 08:17AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : September 16, 2016
Sep-15-16 05:55AM  Coverage initiated on Arena Pharm by FBR & Co. +12.99%
Sep-12-16 10:52AM  How Hedge Funds Were Passing Around Marijuana Stocks in Q2 at Insider Monkey +5.41%
10:29AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : September 12, 2016
Sep-02-16 10:06AM  Arena (ARNA) Beacon Discovery to Boost Research Platform
Sep-01-16 05:00PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
04:30PM  Arena Pharmaceutics Announces Formation of Beacon Discovery PR Newswire
Aug-25-16 06:04AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Aug-23-16 11:20AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : August 23, 2016
Aug-17-16 09:29AM  Biotech Industry on the Upswing after Rocky Start to 2016
Aug-15-16 04:03PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
07:00AM  Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer PR Newswire
Aug-11-16 12:30PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : August 11, 2016
Aug-10-16 01:28PM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
Aug-09-16 07:19AM  Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
06:10AM  ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-08-16 05:38PM  How Will Arena Pharmaceuticals (ARNA) Stock React to Q2 Miss?
04:51PM  Arena Pharmaceuticals reports 2Q loss
04:12PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
02:19PM  What to Expect in Arena Pharmaceuticals Earnings? at Investopedia
07:07AM  Q2 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Aug-01-16 04:01PM  Arena Pharmaceuticals to Release Second Quarter 2016 Financial Results and Provide Corporate Update on Monday, August 8, 2016 PR Newswire
08:56AM  Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Jul-26-16 11:42AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : July 26, 2016
Jul-21-16 08:17AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : July 21, 2016
Jul-20-16 10:10AM  Company News for July 20, 2016
Jul-19-16 12:43PM  Arena Pharmaceuticals (ARNA) Stock Gains as FDA Approves Weight-Loss Drug
10:20AM  Eisai And Arena Pharmaceuticals Get FDA Approval For BELVIQ XR Extended-Release Tablets
09:02AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
08:40AM  Arena Pharma stock rises 8.8% after weight-loss drug is approved at MarketWatch
08:26AM  Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets PR Newswire
Jul-14-16 11:51AM  Eisai, Arena Pharmaceuticals Get Regulatory Approval For VENESPRI In Mexico
08:21AM  Arena Pharmaceuticals stock soars after weight drug approved in Mexico at MarketWatch
08:05AM  Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in Mexico PR Newswire
Jul-05-16 11:38AM  Arena Pharmaceuticals to Slash Workforce By 73% (ARNA) at Investopedia
Jul-01-16 09:37AM  Arena (ARNA) to Cut 73% Workforce, Shifts Focus to Pipeline
Jun-30-16 04:21PM  Arena Pharma to lay off 73% of workforce; shares halted at MarketWatch
04:17PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
04:05PM  Arena Pharmaceuticals Announces Shift to Focus on Proprietary Clinical Stage Pipeline PR Newswire
Jun-28-16 09:31AM  These Biotech Companies Are Prime For a Breakout as the Market for Smoking Cessation Products Heats Up
08:12AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : June 28, 2016
Jun-21-16 09:00AM  Buy Insys Therapeutics Before Medical Marijuana Reaches A Tipping Point at Forbes
Jun-16-16 06:07AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Jun-15-16 11:57AM  Arena Pharmaceuticals Hires Kevin Lind As CFO
11:16AM  Heres Why Traders Are Buzzing about These Five Stocks at Insider Monkey
07:00AM  Arena Pharmaceuticals Announces Appointment of Kevin R. Lind as Chief Financial Officer PR Newswire
Jun-13-16 04:41PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
07:00AM  Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334 PR Newswire
Jun-09-16 08:58AM  Orexigen Stock Gains More than 50% on Markman Hearing
Jun-06-16 07:02AM  Antidote Company's Valuation Misaligned With Growing Crisis +7.49%
Jun-01-16 10:51AM  Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
10:21AM  The Little-Known Reason Arena Pharmaceuticals Could Be a Winner at Motley Fool
08:27AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : June 1, 2016
May-28-16 03:11PM  How Hedge Funds Traded Marijuana Stocks in Q1 at Insider Monkey
May-26-16 07:10PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : May 26, 2016
May-23-16 01:05PM  Drawing Biopharma Concepts With A Crayon at Motley Fool
May-16-16 06:40PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : May 16, 2016
May-13-16 10:21AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q1, 2016 By the Numbers
May-10-16 08:27AM  Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
07:30AM  Boston drug firm's shares slump due to job cuts, cash shortage at American City Business Journals
12:57AM  Edited Transcript of ARNA earnings conference call or presentation 9-May-16 9:00pm GMT
May-09-16 05:14PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
05:07PM  Arena Pharmaceuticals reports 1Q loss
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include APD334, a modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which is in Phase II clinical trials; and Ralinepag that is in Phase II clinical trials for the treatment of pulmonary arterial hypertension. The company's products under development also comprise APD371, an agonist of the cannabinoid-2 receptor that is in Phase I clinical trials for the treatment of pain; Nelotanserin, which is in Phase II clinical trials for the treatment of dementia-associated psychosis; Temanogrel, which is in Phase I clinical trials for thrombotic diseases; and Undisclosed Orphan GPCR that is in pre-clinical development for central nervous system indications. In addition, it manufactures drug products under a toll manufacturing agreement for Siegfried AG. Arena Pharmaceuticals, Inc. has collaboration with Boehringer Ingelheim International GmbH. The company was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
White Christine AnnaDirectorJun 13Sale1.9918,72837,29985,529Jun 15 08:55 PM